glp 1 ra drugs GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders US study suggests GLP-1 RA
Description
Despite all of the benefits we have listed above , incretin mimetics have some undesirable side effects too
Currently, nearly 100 million people globally are affected by DR, and as the prevalence of diabetes continues to rise, this number is expected to grow, posing a significant burden on public health (82)
55% decrease in snacking episodes in the Supresa group Appetite Control : By the end of the study,
J R Soc Interface
For patients first prescribed an ADM in June 2025, 72.2% filled a GLP-1 RA within 60 days
